THE ROLE OF CERVISTA HR HPV TEST IN CERVICAL CANCER SCREENING, A CROSS-SECTIONAL STUDY OF CLINICAL A

来源 :The 6th Biennial Conference of Asia Oceania Research Organis | 被引量 : 0次 | 上传用户:xtchen
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background: The type distribution of high-risk (HR) HPV types associated with cervical neoplasia is somewhat different in China compared to that of Europe or North America, with the most prevalent types being within the A9 species, including HPV types 16, 31, 33, 52 and 58.
其他文献
Objective: To develop and implement a community based model for cervical cancer prevention that allows the communities to manage the screening and the healthcare system to focus resources on evaluatio
会议
El Salvador has one of the worlds highest cervical cancer incidence and mortality rates.To improve cervical cancer screening, the Ministry of Health (MOH), in cooperation with Basic Health Internation
会议
Although HPV vaccination will likely be the ultimate cervical cancer prevention strategy,given its effectiveness, the worldwide familiarity and acceptance of vaccination as a preventive strategy, and
会议
Arbor Vita Corporation, in collaboration with PATH and CICAMS, developed the OncoE6TM Cervical Test ("E6 Test") for settings where ease of test use, short time from sample collection to result, and a
会议
The knowledge that cervical neoplasia are caused by persistent infection with one of the high-risk types of human papilloma virus types and around 70% cervical cancers are caused by HPV 16 or HPV 18 p
会议
Objectives:To describe the experience on scaling up of VIA screening and to assess the diagnosis and management for pre-cancer at BSMMU.
Cervical cancer rates are slowly declining in India and it is now the second most common cancer among women.
会议
Preinvasive neoplasia of the vulva has been recognized for over 90 years, but terminology to describe this disease has been confusing.
会议
Objectives: AP611074 is a new drug that inhibits the interaction of E1/E2 proteins of HPV6/11, blocking HPV replication.We aimed to obtain proof-of-concept of AP611074 in the topical treatment of cond
Objectives:We investigated whether women who underwent subsequent cervical excision during the PATRICIA trial (AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine) benefited from reduced incidenc
会议